Literature DB >> 8024

Comparative doses and costs of antipsychotic medication.

J M Davis.   

Abstract

It is clinically useful to have a table listing the equivalent doses of the various neuroleptics to a standard, such as chlorpromazine. This article derives such data by reviewing double-blind controlled studies that used a flexible dosage schedule of neuroleptics in treating schizophrenic patients. Each neuroleptic is then converted to 100-mg chlorpromazine equivalents. This empirically derived dosage comparability table is compared with a similar table derived from the opinions of experts. Since these comparable doses produce equivalent amounts of antipsychotic activity, the cost to provide such medication was then calculated, and a table comparing the costs of the different neuroleptics was constructed. In absolute amounts, the cost differences between drugs are small. However, for any drug, large savings accrue when the largest possible capsule or tablet to achieve the desired dose is prescribed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 8024     DOI: 10.1001/archpsyc.1976.01770070088010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  34 in total

1.  Emotional experience and expression in schizophrenia and depression.

Authors:  H Berenbaum; T F Oltmanns
Journal:  J Abnorm Psychol       Date:  1992-02

2.  Psychotropic medication and ethnicity: an inpatient survey.

Authors:  K Lloyd; P Moodley
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1992-03       Impact factor: 4.328

3.  Exploratory eye movements in schizophrenic patients and patients with frontal lobe lesions.

Authors:  E Matsushima; T Kojima; S Ohbayashi; H Ando; K Ando; Y Shimazono
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

4.  Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables.

Authors:  O Gureje
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-12       Impact factor: 10.154

5.  Involuntary orofacial movements in hospitalised patients with mental handicap or epilepsy: relationship to developmental/intellectual deficit and presence or absence of long-term exposure to neuroleptics.

Authors:  H A Youssef; J L Waddington
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 6.  Antipsychotic drugs: clinical pharmacology and therapeutic use.

Authors:  J M Davis; R Casper
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

Review 7.  Tardive dyskinesia in non-western countries: a review.

Authors:  A K Pandurangi; Y A Aderibigbe
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

8.  Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Authors:  R A Kiivet; A Llerena; M L Dahl; L Rootslane; J Sánchez Vega; T Eklundh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

9.  Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.

Authors:  D H Wiles; R G McCreadie; A Whitehead
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

10.  A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia.

Authors:  D J King; M Blomqvist; S J Cooper; M M Doherty; M J Mitchell; R C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.